Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2021-04-23 | Mohammad Azab, M.D., M. Sc., M.B.A. served as President and Chief Medical Officer of Astex Pharmaceuticals, Inc. from 2014 to 2020 after holding the position of Chief Medical Officer there commencing in 2009. ... Dr. Azab’s scientific background including his senior management experiencein the pharmaceutical industry and as a board member of a publicly traded company are among the qualifications he brings to the Board and his service as a Director of the Company. |
| 2022-04-25 | Mohammad Azab, M.D., M. Sc., M.B.A. has served on our Board of Directors since January 2021. ... At the end of the last fiscal year, the Compensation Committee was composed of Mohammad Azab, David R. Hoffmann and Gail J. Maderis. ... At the end of the last fiscal year, the Nominating and Corporate Governance Committee was composed of Mohammad Azab, Simon X. Benito, Terrence F. Blaschke and Judith J. Robertson. ... At the end of the last fiscal year, the Research and Development Committee was composed of Mohammad Azab, Terrence F. Blaschke and Gail M. Farfel. |
| 2023-04-27 | Mohammad Azab, M.D., M. Sc., M.B.A. has served on our Board of Directors since January 2021. ... At the end of the last fiscal year, the Compensation Committee was composed of Mohammad Azab, Peter S. Garcia, David R. Hoffmann and Gail J. Maderis. ... The Nominating and Corporate Governance Committee was composed of Mohammad Azab, Terrence F. Blaschke and Judith J. Robertson. ... The Research and Development Committee was composed of Mohammad Azab, Terrence F. Blaschke and Gail M. Farfel. ... Director Compensation for Fiscal 2022: Mohammad Azab, M.D., M. Sc., M.B.A. Fees Earned or Paid in Cash ($) 58,500, Option Awards ($) 23,150, Total ($) 81,650. |
| 2024-08-12 | Mohammad Azab, M.D., M. Sc., M.B.A. has served on our Board of Directors since January 2021. Dr. Azab served as President and Chief Medical Officer of Astex Pharmaceuticals, Inc. from January 2014 to November 2020. Dr. Azab’s scientific background including his senior management experience in the pharmaceutical industry and his service as a board member on multiple publicly traded companies are among the qualifications he brings to our Board of Directors. Director Compensation for Fiscal 2023 shows cash fees of $58,500 and option awards valued at $23,115, totaling $81,615. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22